Back to top
Close
Steve Reitmeister

"Today, I Will Give You
5 Stocks Set to Double Absolutely Free"

Dear Zacks.com Visitor,

I invite you to download a free Special Report that names 5 tickers, each tabbed by a Zacks expert to gain +100% and more in the next 12 months.

One company announced a cancer breakthrough that scored a 79% increase in progression-free survival in Phase III testing. Another is set to gain steam from a $3.45 billion acquisition. Still another has room for price increases that could send margins through the roof. Don't miss these stocks with compelling gain potential.

Mindray Medical: (MR)

(Market Close from NYSE) As of Jan 30, 2015 04:04 PM ET

 Add to portfolio

 ZacksTrade Now

$27.36 USD

27.36
379,775

-0.25 (-0.91%)

Volume: 379,775

Zacks Rank : 3-Hold [?]     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 26.65%
2 Buy 18.84%
3 Hold 10.45%
4 Sell 4.76%
5 Strong Sell 2.56%
S&P 500 10.28%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The way to access to the Zacks Rank

Quote Overview

Stock Activity

Open 27.40
Day Low 27.32
Day High 27.62
52 Wk Low 25.90
52 Wk High 36.59
Avg. Volume 615,069
Market Cap 3.21 B
Dividend 0.46 ( 1.68%)
Beta 1.14

Key Earnings Data

Forward PE 13.84
PEG Ratio 0.86
Current Qtr Est 0.47
Current Yr Est 1.98
Most Accurate Est 0.47
Qtr Earnings ESP[?] 0.00%
Exp Earnings Date 3/2/15
Prior Year EPS 2.05
Exp EPS Growth 16.00%
Industry MED INSTRUMENTS

Earnings ESP (Expected Surprise Prediction) is Zacks’ proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement.

Read more about this innovative method in the Zacks Earnings ESP Guide See all the top Earnings ESP Stocks.

Premium Research for MR

Zacks Rank [?] Hold 3
Zacks Industry Rank 99 / 265 (Top 37%)
Equity Research Report

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 26.65%
2 Buy 18.84%
3 Hold 10.45%
4 Sell 4.76%
5 Strong Sell 2.56%
S&P 500 10.28%

Zacks Rank Education - Learn more about the Zacks Rank

Zacks Rank Home - All Zacks Rank resources in one place

Zacks Premium - The only way to get access to the Zacks Rank

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

Learn to Profit from the Zacks Rank

Zacks Recommendation has been removed. Learn more

Due to overwhelming customer feedback we have removed the Zacks Recommendation. Unfortunately, having two separate rating systems proved far too confusing to most investors. Going forward we will just focus on the Zacks Rank which has a longer and more impressive track record of outperformance. Even though the Zacks Rank is primarily used for stock trading in a 1-3 month time frame, it also can be very helpful for long term investors. To learn more about using the Zacks Rank for long term investing, click here.

Premium Research : Industry Analysis

Top Peers Symbol Zacks Rank
MINDRAY MEDICAL MR
ABIOMED INC ABMD
INOGEN INC INGN
SYNERGETICS USA SURG
EDWARDS LIFESCI EW
ELECTROMED INC ELMD
HANSEN MEDICAL HNSN
HOLOGIC INC HOLX
INTERSECT ENT XENT
IRADIMED CORP IRMD

See all MED INSTRUMENTS Peers>>